Advertisement
YOU ARE HERE: LAT HomeCollectionsMerck Co Inc
IN THE NEWS

Merck Co Inc

FEATURED ARTICLES
BUSINESS
July 13, 2006
Jurors ended their first day of deliberations without a verdict in a lawsuit against Merck & Co. Inc. over whether its pain-relieving drug Vioxx contributed to a New Jersey woman's heart attack.
ARTICLES BY DATE
BUSINESS
October 23, 2008 | times wire services
Drug maker Merck & Co. said it would slash 7,200 jobs as part of a new restructuring program that comes as its third-quarter profit plunged 28% because of a hefty restructuring charge and flat sales. The maker of allergy and asthma treatment Singulair and cervical cancer vaccine Gardasil said it would cut nearly 13% of its workforce to lower overhead and become more competitive in its second major restructuring in less than three years. Merck shares closed down $1.96 at $28.01. Whitehouse Station, N.J.-based Merck took a $612-million charge for restructuring, reducing net income for its third quarter to $1.09 billion, or 51 cents a share.
Advertisement
BUSINESS
December 14, 2007 | From Times Wire Services
The government should reject Merck & Co. Inc.'s third bid to sell a cholesterol-lowering pill without a doctor's prescription, an advisory panel ruled. Advisors to the Food and Drug Administration voted 10 to 2 with one abstention against Merck's proposal for a low-dose, over-the-counter version of its cholesterol fighter Mevacor. FDA officials usually follow the panel's recommendations.
BUSINESS
April 16, 2008 | From the Associated Press
Two new reports involving the painkiller Vioxx raise fresh concerns about how drug companies influence the interpretation and publication of medical research. The reports claim that Merck & Co. frequently paid academic scientists to take credit for research articles prepared by company-hired medical writers, a practice called ghostwriting.
BUSINESS
August 23, 2005 | From Reuters
Britons who believe they suffered after taking Merck & Co. Inc.'s painkiller Vioxx plan to sue the drug maker in the U.S. courts next year, a law firm said. Attorney Gerard Dervan said it made sense for the 150 British plaintiffs to pursue Merck in the U.S. courts because British authorities had so far decided not to provide legal aid and British courts could force the plaintiffs to pay Merck's costs if they lost.
NATIONAL
April 13, 2007 | From Times Wire Reports
A painkiller proposed as a successor to Vioxx should not be approved, a panel of federal health advisors recommended to the FDA. The nonbinding 20-1 vote was on the prescription drug Arcoxia, made by Merck & Co. Inc. A Food and Drug Administration drug safety expert had told the panel the drug might substantially increase the risk of stroke and heart attack and was no more effective for pain relief than other medicines in the same class.
BUSINESS
December 25, 1996 | Times Staff and Wire Reports
Merck & Co. Inc., claiming exclusive rights to distribute a chicken pox vaccine in the United States and Canada, sued four affiliates of SmithKline Beecham in an effort to block them from distributing their vaccine in the United States. Named as defendants are SmithKline Beecham U.S. affiliates SKB Pharmaceuticals Co., SKB Holdings Corp., SKB Corp. and the Belgian affiliate SKB Biologicals. No one at SmithKline's U.S. offices in Philadelphia could be reached for comment.
BUSINESS
December 1, 2004 | From Reuters
New York filed a lawsuit Tuesday against Merck & Co. Inc., claiming the state's pension fund lost $171 million from its investment in the drug maker after the company recalled its Vioxx painkiller. New York State Comptroller Alan Hevesi said he was seeking to be the lead plaintiff in a shareholder class-action suit against Merck and aimed to have the shareholder cases against the company consolidated in U.S. District Court in New Jersey.
NEWS
May 22, 1992 | MAURA DOLAN, TIMES ENVIRONMENTAL WRITER
Spurred by advances in biotechnology, drug companies are showing renewed interest in exploring nature for new medicines. At the forefront of the trend is pharmaceutical giant Merck & Co. Inc., which has entered into an agreement with a scientific institute in Costa Rica to screen plants, insects and microorganisms found in the tropical nation's lush forests.
BUSINESS
April 20, 1993 | From Associated Press
Fifteen major U.S. and European pharmaceutical companies on Monday announced that they will share information from AIDS research efforts in an attempt to reduce drug-development time. After more than a year of formal discussions, the group, which includes Merck & Co., Pfizer Inc., Glaxo of Britain and Switzerland's Hoffman-La Roche, has agreed to exchange clinical data and drug supplies so that antiviral medicines can be tested in the best possible combinations.
BUSINESS
February 8, 2008 | From the Associated Press
In one of the biggest U.S. healthcare fraud settlements ever, Merck & Co. will pay $671 million to settle claims it overcharged the government for four popular drugs and bribed doctors to prescribe its drugs, federal prosecutors said Thursday.
BUSINESS
January 23, 2008 | From Bloomberg News
Merck & Co. and Schering-Plough Corp. suspended television ads Tuesday for the cholesterol pills Vytorin and Zetia after a study questioned the benefit of the medicines. The Vytorin commercials were among the most widely aired drug ads, featuring people dressed as food items to show the pill lowers cholesterol from food as well as from genetics. The ads were voluntarily and temporarily halted, Schering-Plough spokesman Lee Davies said.
BUSINESS
January 19, 2008 | From Reuters
More than 3,000 former users of Merck & Co.'s withdrawn Vioxx pain drug have signed up to take part in a $4.85-billion settlement deal that a federal judge said Friday was in the best interests of both sides. Lawyers for Merck and plaintiffs who claim to have been harmed by Vioxx were in U.S. District Court to give a status report on the settlement to Judge Eldon Fallon, who had presided over all federal Vioxx trials and is overseeing the settlement process.
BUSINESS
December 14, 2007 | From Times Wire Services
The government should reject Merck & Co. Inc.'s third bid to sell a cholesterol-lowering pill without a doctor's prescription, an advisory panel ruled. Advisors to the Food and Drug Administration voted 10 to 2 with one abstention against Merck's proposal for a low-dose, over-the-counter version of its cholesterol fighter Mevacor. FDA officials usually follow the panel's recommendations.
BUSINESS
November 10, 2007 | Molly Selvin, Times Staff Writer
Merck & Co.'s decision to pay $4.85 billion to settle tens of thousands of claims from patients who took the popular painkiller Vioxx may stiffen the resolve of other companies facing litigation over pharmaceutical products or other consumer goods. The settlement, announced Friday, may also vindicate the drug maker's initial strategy of aggressively fighting virtually every injury claim, legal experts said.
NATIONAL
November 9, 2007 | From Times Staff and Bloomberg News
Merck & Co., after setting aside nothing to resolve liability over its Vioxx painkiller, may pay about $5 billion to settle claims that it hid the health risks of its withdrawn drug, three lawyers with direct knowledge of the accord said. Merck, the third-largest U.S. drug maker, pulled Vioxx off the market in 2004 after a study showed it raised the risk of heart attacks in some patients.
HEALTH
May 14, 2007 | Sandra G. Boodman, Washington Post
When Merck launched a multimillion-dollar marketing campaign last year to promote Gardasil, its new vaccine to prevent cervical cancer, company officials probably did not anticipate that its signature phrase -- "one less" -- would apply not just to malignancies but also to physicians. Yet that slogan has come to symbolize the response of doctors.
BUSINESS
August 12, 1993 | JAMES S. GRANELLI and ANNE MICHAUD, TIMES STAFF WRITERS
Community pharmacies, banding together to fight what they describe as price gouging, filed two class-action lawsuits Wednesday accusing major drug manufacturers and distributors of charging them drastically higher prices than those charged to hospitals, HMOs and mail-order houses. Filed in federal court in San Francisco, the suits--together with three state actions filed last week--accuse at least eight manufacturers and distributors of wide-scale price discrimination.
BUSINESS
July 26, 2007 | From Times Wire Services
The increased heart risk from Vioxx, Merck & Co.'s withdrawn arthritis medicine, begins much earlier than after 18 months of use, according to a study contradicting assertions by the drug maker and its scientists. The 2,434-patient study, published in the New England Journal of Medicine, was halted early when the medicine was pulled from the market in September 2004. Although the median duration of treatment was only 7.
BUSINESS
July 4, 2007 | From Times Wire Services
A federal judge ruled that Merck & Co. must defend lawsuits over its Vioxx painkiller, rejecting an argument that U.S. regulations preclude patients from claiming they weren't warned about the drug's risks. U.S. District Judge Eldon Fallon in New Orleans denied Merck's request to dismiss two cases on the grounds that the Vioxx warning label was approved by the Food and Drug Administration.
Los Angeles Times Articles
|